ERBB2 and neoplasm: The SOLTI-1114 PAMELA study by Sanz-Moreno et al. demonstrated RANK and RANK-L were more frequently detected in HER2-positive tumours that acquired resistance to anti-HER2 therapies than in treatment-naive ones [15].